Crohn’s & Colitis Foundation Co-Funded Study Sheds Light On Immune System, Inflammation

Crohn’s & Colitis Foundation Co-Funded Study Sheds Light On Immune System, Inflammation
shutterstock_148825229A new study on a potential regulation mechanism of autoimmunity and anti-tumor immunity entitled “CEACAM1 regulates TIM-3-mediated tolerance and exhaustion” was published in Nature by Yu-Hwa Huang, part of Dr. Richard S. Blumberg’s group from the Division of Gastroenterology at Harvard Medical School in Boston. The study was funded by the National Institutes of Health, Harvard Digestive Diseases Center, and a Research Fellowship Award from the Crohn's and Colitis Foundation of America. The research team revealed a partner for the important immune protein, named T-cell immunoglobulin domain and mucin domain-3 (TIM-3), which is expressed by stimulated cells upon specific signals and regulate the activity of the cells. Permanently activated cells, a condition called "exhaustion," is an immunological feature of chronic viral infections, such as HIV, and cancer. Therefore TIM-3 seems to be a potential target for the development of new therapies for cancer and viral infections. "There has been a lot of confusion around TIM-3 -- how does it both inhibit and activate the immune system," said Richard Blumberg, chief of the Division of Gastroenterology, Hepatology and Endoscopy at Brigham and Women's
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *